BBOT's BBO-11818 Shows Promising Preclinical Data as panKRAS Inhibitor
Event summary
- BBOT published preclinical data in Cancer Discovery showing BBO-11818 is a potent and selective panKRAS inhibitor targeting KRAS in both ON and OFF states.
- BBO-11818 demonstrated significant tumor growth inhibition across multiple tumor types and strong combination potential with other anti-tumor agents.
- Preliminary clinical data from the Phase 1 KONQUER-101 trial showed encouraging anti-tumor activities and differentiated safety.
- Additional data from the KONQUER-101 trial expected in the second half of 2026, with combination studies with BBO-10203 anticipated later in 2026.
The big picture
BBOT's BBO-11818 represents a significant advancement in targeting KRAS mutations, addressing a critical unmet need in oncology. The preclinical data and early clinical results position BBO-11818 as a potential foundational therapy for KRAS-driven tumors, which are among the most prevalent and challenging to treat. The strategic collaboration with Frederick National Lab and Lawrence Livermore National Laboratory underscores the scientific rigor behind this development.
What we're watching
- Clinical Efficacy
- How the additional data from the KONQUER-101 trial in the second half of 2026 will impact the perceived clinical efficacy of BBO-11818.
- Combination Therapy
- Whether the combination of BBO-11818 with BBO-10203 can enhance therapeutic outcomes and expand treatment options for KRAS-driven tumors.
- Regulatory Pathway
- The pace at which BBOT can advance BBO-11818 through clinical trials and secure regulatory approvals for broader use.
Related topics